TY - JOUR
T1 - Clinical phenotype and mutation spectrum of alzheimer’s disease with causative genetic mutation in a chinese cohort
AU - Mao, Chenhui
AU - Li, Jie
AU - Dong, Liling
AU - Huang, Xinying
AU - Lei, Dan
AU - Wang, Jie
AU - Chu, Shanshan
AU - Liu, Caiyan
AU - Peng, Bin
AU - Román, Gustavo C.
AU - Cui, Liying
AU - Gao, Jing
N1 - Funding Information:
This work was supported by the CAMS Innovation Fund For Medical Sciences (CIFMS) (No. 2016-I2M-1-004, 2020-I2M-C&T-B-010); National Natural Science Foundation of China (81550021, 30470618); National key Research and Development Program of China (2016YFC1306300, 2020YFA0804500).
Publisher Copyright:
© 2021 Bentham Science Publishers.
PY - 2021
Y1 - 2021
N2 - Background: Alzheimer’s disease with a causative genetic mutation (AD-CGM) is an un-common form, characterized by a heterogeneous clinical phenotype and variations in the genotype of racial groups affected. Objective: We aimed to systemically describe the phenotype variance and mutation spectrum in the large sample size of the Peking Union Medical College Hospital (PUMCH) cohort, Beijing, China. Methods: Next-generation sequencing (NGS) was carried out in 1108 patients diagnosed with demen-tia. A total of 40 Han Chinese patients with three AD gene mutations were enrolled. A systemic review of all the patients was performed, including clinical history, neurocognitive assessment, brain magnetic resonance imaging, and cerebrospinal fluid (CSF) biomarkers. Results: We studied the following gene mutation variants: 12 AβPP, 13 PSEN1, and 9 PSEN2, and 23 among them were novel. Most of them were early-onset, but PSEN1 mutation carriers had the young-est onset age. The commonest symptoms were similar to those of AD, including an amnestic syn-drome, followed by psychiatric symptoms and movement disorder. On MRI, parietal and posterior temporal atrophy was prominent in PSEN1 and PSEN2 mutation carriers, while AβPP mutation carriers had more vascular changes. The CSF biomarkers profile was indistinguishable from sporadic AD. Conclusion: We identified a small group of AD-CGM subjects representing 3.6% among more than 1000 demented patients in the PUMCH cohort. These subjects usually presented with early-onset dementia and exhibited significant clinical and genetic heterogeneity. Identification required complete screening of genetic mutations using NGS. Although family history was usually present, we found non-familial cases of all three genetic mutations.
AB - Background: Alzheimer’s disease with a causative genetic mutation (AD-CGM) is an un-common form, characterized by a heterogeneous clinical phenotype and variations in the genotype of racial groups affected. Objective: We aimed to systemically describe the phenotype variance and mutation spectrum in the large sample size of the Peking Union Medical College Hospital (PUMCH) cohort, Beijing, China. Methods: Next-generation sequencing (NGS) was carried out in 1108 patients diagnosed with demen-tia. A total of 40 Han Chinese patients with three AD gene mutations were enrolled. A systemic review of all the patients was performed, including clinical history, neurocognitive assessment, brain magnetic resonance imaging, and cerebrospinal fluid (CSF) biomarkers. Results: We studied the following gene mutation variants: 12 AβPP, 13 PSEN1, and 9 PSEN2, and 23 among them were novel. Most of them were early-onset, but PSEN1 mutation carriers had the young-est onset age. The commonest symptoms were similar to those of AD, including an amnestic syn-drome, followed by psychiatric symptoms and movement disorder. On MRI, parietal and posterior temporal atrophy was prominent in PSEN1 and PSEN2 mutation carriers, while AβPP mutation carriers had more vascular changes. The CSF biomarkers profile was indistinguishable from sporadic AD. Conclusion: We identified a small group of AD-CGM subjects representing 3.6% among more than 1000 demented patients in the PUMCH cohort. These subjects usually presented with early-onset dementia and exhibited significant clinical and genetic heterogeneity. Identification required complete screening of genetic mutations using NGS. Although family history was usually present, we found non-familial cases of all three genetic mutations.
KW - Alzheimer’s disease
KW - Amyloid β precursor protein
KW - Causative genetic mutation
KW - Next-generation sequencing
KW - Phenotype
KW - Presenilin gene
KW - Variants
KW - Alzheimer Disease/genetics
KW - Mutation/genetics
KW - Humans
KW - Middle Aged
KW - Male
KW - Presenilin-1/genetics
KW - Amyloid beta-Protein Precursor/genetics
KW - China
KW - Adult
KW - Female
KW - High-Throughput Nucleotide Sequencing
KW - Presenilin-2/genetics
KW - Asians
KW - Cohort Studies
UR - http://www.scopus.com/inward/record.url?scp=85115040262&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115040262&partnerID=8YFLogxK
U2 - 10.2174/1567205018666210608120339
DO - 10.2174/1567205018666210608120339
M3 - Article
C2 - 34102969
AN - SCOPUS:85115040262
SN - 1567-2050
VL - 18
SP - 265
EP - 272
JO - Current Alzheimer Research
JF - Current Alzheimer Research
IS - 3
ER -